IGM Biosciences Inc

IGM Biosciences, Inc. operates as a biotechnology company, which develops antibodies for the treatment of cancer. It offers the IgM platform to expand upon the inherent properties of IgM antibodies and to allow for the rapid development of engineered therapeutic antibodies. The firm’s product pipeline includes IGM-2323, which is a CD20 x CD3 bispecific IgM antibody designed to treat patients with B cell Non-Hodgkin's lymphoma and other B cell malignancies, IGM-8444, which is an IgM antibody targeting Death Receptor 5 for the treatment of patients with solid and hematologic malignancies, and IGM-7354, which will target the delivery of IL-15 with the goal of inducing immune cell stimulation and proliferation. The company was founded in 2010 and is headquartered in Mountain View, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

IGM Biosciences reports progress in clinical development and strategic shifts

IGM Biosciences showcases progress in clinical development and financial performance.
Strategic shifts towards autoimmune indications present market opportunities.
Management addresses concerns and highlights safety profiles of key product candidates.
Potential for partnerships and differentiation in oncology and autoimmune diseases discussed.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

STOCKHOLM , Sept. 1, 2023 /PRNewswire/ -- Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that it will host a key opinion leader webcast on the current and future HCC (primary liver cancer) treatment landscape, including how treatment challenges and needs in HCC differs from most other cancers.

Medivir Hosts Expert Perspectives Webcast on the Evolving Treatment Landscape and the Unique Treatment Challenges in HCC

Continued tumor control in the liver in 7 of the first 10 patients after three months of treatment The patient who benefited the longest from fostrox + Lenvima® remains on treatment after 12 months, with tumor reduction maintained Consistently good safety and tolerability profile STOCKHOLM , Aug. 14, 2023 /PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today that the 15th patient with advanced hepatocellular carcinoma (HCC) has been included in the ongoing phase 2a study. The study evaluates safety and efficacy with the candidate drug fostrox in combination with Lenvima® in patients for whom current first- or second-line treatment has proven ineffective or is not tolerable.

Promising tumor control for fostrox in combination with Lenvima in ongoing phase 2a study in HCC, 15th patient included

STOCKHOLM , Aug. 7, 2023 /PRNewswire/ -- Medivir AB (Nasdaq: MVIR) (Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announced today the formation of a Scientific Advisory Council as the company intensifies its plans for next phase of development. In February, Medivir announced positive, preliminary results from the dose escalation cohorts of its candidate drug fostrox, in combination with Lenvima® and initiated the phase 2a expansion cohort.

Medivir partners with world-leading liver cancer experts in new Scientific Advisory Council

IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $1.43 per share in line with the Zacks Consensus Estimate. This compares to loss of $1.33 per share a year ago.

IGM Biosciences, Inc. (IGMS) Reports Q2 Loss, Misses Revenue Estimates

– Continued progress in clinical development across portfolio – – Public equity offering and concurrent private placement with gross proceeds of $120.0 million –

IGM Biosciences Announces Second Quarter 2023 Financial Results

MOUNTAIN VIEW, Calif., July 03, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the closing of its previously announced upsized underwritten public offering of 1,597,827 shares of its voting common stock and 9,000,000 shares of its non-voting common stock and including the full exercise of the underwriters' option to purchase 1,589,673 shares of its voting common stock, at a public offering price of $8.00 per share. All of the shares in the public offering were sold by IGM and delivered to purchasers on June 26, 2023, other than with respect to 5,625,000 shares of non-voting common stock, delivery of which occurred on July 3, 2023.

IGM Announces Closing of Upsized Public Offering and Concurrent Private Placement and Full Exercise of the Underwriters' Option to Purchase Additional Shares

IGM Biosciences, Inc. (IGMS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Strength Seen in IGM Biosciences, Inc. (IGMS): Can Its 7.6% Jump Turn into More Strength?

MOUNTAIN VIEW, Calif., June 22, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced the pricing of its upsized underwritten public offering of 3,285,327 shares of its voting common stock and 7,312,500 shares of its non-voting common stock, in each case at a price to the public of $8.00 per share. In addition, IGM has granted the underwriters a 30-day option to purchase up to an additional 1,589,673 shares of its voting common stock at the public offering price, less underwriting discounts and commissions. All of the shares in the public offering will be sold by IGM. The public offering is expected to close on or about June 26, 2023, subject to satisfaction of customary closing conditions.

IGM Announces Pricing of $107.3 Million Upsized Public Offering and Concurrent Private Placement

MOUNTAIN VIEW, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (NASDAQ: IGMS) today announced that it intends to offer and sell an aggregate of $100.0 million of shares of its common stock and, in lieu of common stock to certain investors that so choose, non-voting common stock, in an underwritten public offering and concurrent private placement. In addition, IGM intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares offered in the public offering at the public offering price, less underwriting discounts and commissions. All of the securities offered in the proposed public offering will be sold by IGM.

IGM Announces Proposed Public Offering and Concurrent Private Placement

STOCKHOLM , June 19, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces today that the company's patent application, covering both substance claims for fostroxacitabine bralpamide (fostrox) and its use for liver cancer treatment, has recently been approved by the Chinese patent authority. Corresponding patents have already been granted in the USA, the EU, Japan and a large number of other countries, mainly in Asia.

Medivir's patent application for fostrox approved in China

– Additional data from Phase 1 combination with FOLFIRI continues to show encouraging activity in median third-line metastatic colorectal cancer patients –

IGM Biosciences Announces Update on IGM-8444 Phase 1 Trial and Future Clinical Development

STOCKHOLM , June 2, 2023 /PRNewswire/ --  Medivir AB (NASDAQ Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces today that a safe dose has been established for treatment with the drug candidate fostroxacitabine bralpamide (fostrox) in combination with Keytruda® in the initial dose escalation part (phase 1b) of the company's 1b/2a study in hepatocellular carcinoma (HCC). In the ongoing expansion part of the study (phase 2a) Medivir is focusing on the fostrox and Lenvima combination and intends to explore the possibility of fostrox in a triple combination together with immunotherapy in earlier lines.

Medivir has completed the dose escalation part (phase 1b) of the 1b/2a study in HCC and focuses on the combination of fostrox and Lenvima

STOCKHOLM , June 1, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the Redeye Growth Day, today June 1, 2023. CEO Jens Lindberg will participate in an In Focus interview led by Redeye analyst Richard Ramanius, with focus on our proprietary project fostroxacitabine bralpamide (fostrox), at 13.35 CEST.

Medivir to present at the Redeye Growth Day

Imvotamab, a CD20 x CD3 bispecific monoclonal antibody, offers potential for deeper B cell depletion than currently approved therapies Imvotamab, a CD20 x CD3 bispecific monoclonal antibody, offers potential for deeper B cell depletion than currently approved therapies

IGM Biosciences Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis

STOCKHOLM , May 31, 2023 /PRNewswire/ -- Medivir AB (publ) ("Medivir") (Nasdaq Stockholm: MVIR) today announces that the number of shares and votes in Medivir has changed during May 2023 as a result of the previously announced share issue of 970,500 shares of series C and the reclassification of 105,750 shares of series C into ordinary shares, which was carried out as part of the long-term incentive program for key employees within the Medivir group adopted by the annual general meeting held on 4 May 2023. As of 31 May 2023, the total number of shares in Medivir amounts to 56,706,151 of which 55,841,401 are ordinary shares with one (1) vote each and 864,750 are shares of series C with one tenth (1/10) vote each.

Change in the number of shares and votes in Medivir AB (publ)

– Event to be webcast live on Friday, June 2, 2023 at 7:00 p.m. ET – MOUNTAIN VIEW, Calif.

IGM Biosciences to Host Conference Call and Webcast to Provide IGM-8444 Clinical Update

STOCKHOLM , May 30, 2023 /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR), a pharmaceutical company focused on developing innovative treatments for cancer in areas of high unmet medical need, announces that the company will participate at the ABGSC Life Science Summit today May 30, 2023. CEO Jens Lindberg will present the company and its plan for the ongoing clinical study with fostroxacitabine bralpamide (fostrox) at 13.30 CET.

Medivir to present at the ABGSC Life Science Summit

HUDDINGE, Sweden , May 16, 2023 /PRNewswire/ -- In light of the incentive program adopted by the annual general meeting of Medivir AB (publ) ("Medivir") on 4 May 2023 ("LTIP 2023"), it is today announced that the board of directors of Medivir has resolved on (i) a share issue of 970,500 shares of series C, (ii) repurchase of the 970,500 shares of series C, (iii) reclassification of 105,750 shares of series C into ordinary shares and (iv) partial execution of the annual general meeting's resolution on transfer of own ordinary shares by transferring 105,750 own ordinary shares to participants in LTIP 2023. Aktieinvest FK AB will subscribe for all 970,500 shares of series C at a subscription price of SEK 0.5 per share, equal to the quota value of the shares.

Issue, repurchase and reclassification of shares of series C and transfer of ordinary shares under LTIP 2023

IGM Biosciences, Inc. (IGMS) came out with a quarterly loss of $1.33 per share versus the Zacks Consensus Estimate of a loss of $1.37. This compares to loss of $1.53 per share a year ago.

IGM Biosciences, Inc. (IGMS) Reports Q1 Loss, Lags Revenue Estimates

– Randomized clinical trial of IGM-8444 plus FOLFIRI and bevacizumab in second line metastatic colorectal cancer underway –

IGM Biosciences Announces First Quarter 2023 Financial Results and Provides Corporate Update

STOCKHOLM , May 4, 2023 /PRNewswire/ -- The annual general meeting in Medivir AB (publ), held earlier today on 4 May 2023, resolved to adopt new articles of association, whereby the share class A is removed and shares of series B are reclassified to ordinary shares. All of the company's existing shares as of today consist of shares of series B and there are no shares of series A outstanding.

Execution of the annual general meeting's resolution on the removal of share class in Medivir AB (publ)

STOCKHOLM , May 4, 2023 /PRNewswire/ -- Medivir Aktiebolag (publ) held its annual general meeting today on 4 May 2023. The annual general meeting was held by physical presence of shareholders and with the option for shareholders to exercise their voting rights by advance voting (postal voting).

Resolutions at the Annual General Meeting in Medivir on 4 May 2023

MOUNTAIN VIEW, Calif., April 19, 2023 (GLOBE NEWSWIRE) -- IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that Fred Schwarzer, Chief Executive Officer, will participate in a virtual fireside chat at the Stifel 2023 Targeted Oncology Days on Wednesday, April 26, 2023, at 3:00 p.m. EDT.

IGM Biosciences to Present at the Stifel 2023 Targeted Oncology Days

Presentations highlight data from across all oncology pipeline programs Presentations highlight data from across all oncology pipeline programs

IGM Biosciences Announces Six Presentations at the American Society for Cancer Research Annual Meeting 2023

IGM Biosciences, Inc. (NASDAQ:IGMS ) Q4 2022 Earnings Conference Call March 30, 2023 4:30 PM ET Company Participants Fred Schwarzer – Chief Executive Officer Misbah Tahir – Chief Financial Officer Chris Takimoto – Chief Medical Officer Mary Beth Harler – President-IGM Autoimmunity and Inflammation Bruce Keyt – Chief Scientific Officer Conference Call Participants Stephen Willey – Stifel Greg Harrison – Bank of America Michael Schmidt – Guggenheim Roger Song – Jefferies Joel Beatty – Baird Noah Eisenberg – JPMorgan Leonid Timashev – RBC Capital Markets Asthika Goonewardene – Truist Operator Good day, everyone, and welcome to the IGM Biosciences' Fourth Quarter and Full Year 2022 Financial Results and Corporate Update Call. Today's call is being recorded.

News for IGM Biosciences Inc Stock (IGMS)